Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2019-09-12
Imcyse to present positive results in EAE model of multiple sclerosis at ECTRIMS 2019
2019-08-27
Imcyse reports successful first-in-human phase 1B study in type 1 diabetes with IMCY-0098
2019-08-05
Imcyse announces changes in management and board, appoints Thomas Taapken as Executive Chairman
2019-06-18
Imcyse secures total of €35M in Series B financing round and additional grants

©imcyse 2023